Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 195

1.

Histopathology of breast carcinoma following neoadjuvant systemic therapy: a common association between letrozole therapy and central scarring.

Thomas JS, Julian HS, Green RV, Cameron DA, Dixon MJ.

Histopathology. 2007 Aug;51(2):219-26.

PMID:
17650216
[PubMed - indexed for MEDLINE]
2.

Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy.

Smith IE.

J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):289-93.

PMID:
14623523
[PubMed - indexed for MEDLINE]
3.

Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy.

Krainick-Strobel UE, Lichtenegger W, Wallwiener D, Tulusan AH, Jänicke F, Bastert G, Kiesel L, Wackwitz B, Paepke S.

BMC Cancer. 2008 Feb 26;8:62. doi: 10.1186/1471-2407-8-62.

PMID:
18302747
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
[PubMed - indexed for MEDLINE]
5.

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.

Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS.

J Clin Oncol. 2009 Jun 1;27(16):2630-7. doi: 10.1200/JCO.2008.18.8391. Epub 2009 Apr 20.

PMID:
19380449
[PubMed - indexed for MEDLINE]
Free Article
6.

Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole.

Miller WR, Larionov A, Renshaw L, Anderson TJ, Walker JR, Krause A, Sing T, Evans DB, Dixon JM.

J Clin Oncol. 2009 Mar 20;27(9):1382-7. doi: 10.1200/JCO.2008.16.8849. Epub 2009 Feb 17.

PMID:
19224856
[PubMed - indexed for MEDLINE]
Free Article
7.

Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole.

Miller WR, Larionov A.

Breast Cancer Res. 2010;12(4):R52. doi: 10.1186/bcr2611. Epub 2010 Jul 20.

PMID:
20646288
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes.

Dixon JM, Jackson J, Renshaw L, Miller WR.

J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):295-9. Review.

PMID:
14623524
[PubMed - indexed for MEDLINE]
9.

Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.

Semiglazov VF, Semiglazov VV, Dashyan GA, Ziltsova EK, Ivanov VG, Bozhok AA, Melnikova OA, Paltuev RM, Kletzel A, Berstein LM.

Cancer. 2007 Jul 15;110(2):244-54.

PMID:
17538978
[PubMed - indexed for MEDLINE]
Free Article
10.

Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen.

Miller WR, Dixon JM, Macfarlane L, Cameron D, Anderson TJ.

Eur J Cancer. 2003 Mar;39(4):462-8.

PMID:
12751376
[PubMed - indexed for MEDLINE]
11.

Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.

Ellis MJ, Tao Y, Young O, White S, Proia AD, Murray J, Renshaw L, Faratian D, Thomas J, Dowsett M, Krause A, Evans DB, Miller WR, Dixon JM.

J Clin Oncol. 2006 Jul 1;24(19):3019-25. Epub 2006 Jun 5.

PMID:
16754938
[PubMed - indexed for MEDLINE]
Free Article
12.

Aromatase inhibitors: cellular and molecular effects.

Miller WR, Anderson TJ, White S, Larionov A, Murray J, Evans D, Krause A, Dixon JM.

J Steroid Biochem Mol Biol. 2005 May;95(1-5):83-9.

PMID:
16002280
[PubMed - indexed for MEDLINE]
13.

Neoadjuvant endocrine therapy for postmenopausal patients with hormone receptor-positive early breast cancer: a new concept.

Iwata H.

Breast Cancer. 2011 Apr;18(2):92-7. doi: 10.1007/s12282-010-0233-6. Epub 2010 Dec 8. Review.

PMID:
21140250
[PubMed - indexed for MEDLINE]
14.

Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.

Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M.

J Natl Cancer Inst. 2008 Oct 1;100(19):1380-8. doi: 10.1093/jnci/djn309. Epub 2008 Sep 23.

PMID:
18812550
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Review of the development of letrozole and its use in advanced breast cancer and in the neoadjuvant setting.

Bhatnagar AS.

Breast. 2006 Feb;15 Suppl 1:S3-13. Review.

PMID:
16500235
[PubMed - indexed for MEDLINE]
16.

Letrozole in the treatment of breast cancer.

Mouridsen HT, Bhatnagar AS.

Expert Opin Pharmacother. 2005 Jul;6(8):1389-99. Review.

PMID:
16013988
[PubMed - indexed for MEDLINE]
17.

Estrogen receptors evolution in neoadjuvant aromatase inhibitor (AI) therapy for breast cancer in elderly women: stability of hormonal receptor expression during treatment.

Salmon RJ, Alran S, Malka I, de Cremoux P, Rosty C, Languille O, Campana F; Breast Group of the Institut Curie, Sigal-Zafrani B.

Am J Clin Oncol. 2006 Aug;29(4):385-8.

PMID:
16891867
[PubMed - indexed for MEDLINE]
18.

Invasive lobular carcinoma: response to neoadjuvant letrozole therapy.

Dixon JM, Renshaw L, Dixon J, Thomas J.

Breast Cancer Res Treat. 2011 Dec;130(3):871-7. doi: 10.1007/s10549-011-1735-4. Epub 2011 Aug 26.

PMID:
21870129
[PubMed - indexed for MEDLINE]
19.

An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.

Henriksen KL, Rasmussen BB, Lykkesfeldt AE, Møller S, Ejlertsen B, Mouridsen HT.

Acta Oncol. 2009;48(4):522-31. doi: 10.1080/02841860802676383.

PMID:
19173092
[PubMed - indexed for MEDLINE]
20.

Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.

Lane HA, Lebwohl D.

Semin Oncol. 2006 Apr;33(2 Suppl 7):S18-25. Review.

PMID:
16730273
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk